<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

Novel Data For MBP-Induced EAE Presented at NeuroImmunology Conference

Posted by MD Biosciences on Mar 10, 2020 10:20:22 AM

Due to the clinical and pathological similarities of experimental autoimmune encephalomyelitis (EAE) and Multiple Sclerosis (MS), EAE  is a model for the study of human demyelinating disease. Both EAE and MS are characterized by a relapsing-remitting disease course with subsequent progressive disability. EAE is characterized by chronic inflammatory demyelination of the central nervous system (CNS) and involves autoimmune CD4+ Th1 cells. These cells develop in the peripheral lymphoid organ and travel to the CNS causing an immune response. The development of T cells is controlled largely by the expression of various cytokines, as well as cellular adhesion molecules.

 

This past month in Paris, our scientists presented at the NeuroImmunology Conference, where they shared novel data in the Myelin Basic Protein (MBP) Induced model used to mimic Multiple Sclerosis (MS). This model is a powerful tool for studying disease pathogenesis as well as potential therapeutic interventions. Below find our poster data. 

 

When conducting MS research,  administration of one dose of MPB in a Lewis rat leads to a single relapse that is characterized by hind paw paralysis. This can be characterized histologically, by infiltration of mononuclear cells to the cervical spinal cord and formation of foci. This model is self-limiting and does not show demyelination.

 

 

Screenshot 2020-03-04 13.16.39

 

 

Other MS-EAE Models at MD Biosciences: 

PLP

MBP

MOG


 

Interested to learn about customizable models for neurodegenerative disease research? Contact us today! 

Contact Us!

Read More

Topics: Neuro/CNS, preclinical research, translational research, disease models, Neuroscience, NeuroImmunology

MD Biosciences Runs NeuroScientific Study: Publishes Positive Results in Fight Against Alzheimer's

Posted by MD Biosciences on Aug 5, 2019 9:46:44 AM

View Publication Here

Our team of neuroscience specialists ran a preclinical study with NeuroScientific Biopharmaceuticals in hopes of progressing towards a human trial later in the year for Alzheimer's. Using lead drug candidate EmtinB known to stimulate the reformation of the neuronal network and restore function of damaged nerve cells, the nerve cells were successfully able to communicate again in this study. In fact, EmtinB was able to stimulate regeneration of nerve cells by more than 300% compared to the control. This is significant in affecting synapse loss, a key contributor of cognitive impairment. Together, we are paving the way for successful therapeutic treatment options for Alzheimer's. Learn about our neurodegenerative animal models, behavioral assessments and other neuroscience research services here! 

Read More

Topics: CRO/outsourcing, Neuro/CNS, preclinical research, Behavioral Research, Neuroscience, Nerve Injury, Alzheimer's

MD Biosciences Launches Neuroscience Services Website: featuring neuropathic pain, neurodegenerative disease models and electrophysiology capabilities

Posted by MD Biosciences on Jun 7, 2019 9:20:59 AM

Now live: a website dedicated to MD Biosciences' cutting-edge neurological and CNS research services offered through our Neuroscience Research Laboratories. Our facilities are fitted with state-of-the-art equipment and technologies for preclinical and translational studies, featuring clinically-relevant read outs and endpoints. Specialties include studies of neuropathic, acute and chronic pain and neurodegenerative/neuroinflammatory diseases. Unique pig translational models and electrophysiology capabilities compliment rodent capabilities and accelerate your program towards their next objectives and milestones. Contact our team today! 651-641-1770 or info@mdbiosciences.com 
Visit Neuroscience Services Website

Read More

Topics: Pain, news, Neuro/CNS, in vivo pain models, post-operative pain, Biomarkers, neuropathic pain, Neuropathy, assays, Batch Release Testing, preclinical research, translational research, Electrophysiology, Behavioral Research, porcine model, Neuroscience, Nerve Injury

Now Offering Synaptic Imaging Assay For Cognition and Neurodegenerative Disease Research

Posted by MD Biosciences on Mar 5, 2019 10:18:22 AM

 A powerful method for cognition, learning and degenerative disease research

 

MD Biosciences offers a synaptic imaging assay for evaluating the effect of different treatments on synapse formation and identification. This assay allows the estimation of inhibitory/excitatory synapses ratio and synaptic strength, a powerful method advancing cognition, learning and degenerative disease research and treatment options. 

Screenshot 2019-03-05 10.13.19

Unique Readouts:

  • Synaptic Count
  • Synaptic Strength
  • Identification of synapse type (excitatory/inhibitory)

 

Call or contact us today for more information!

Contact Us!

 

Read More

Topics: Neuro/CNS, assays, Neuroscience, Nerve Injury, cognition research

Senerga Cell-based Assay for Nerve Injury

Posted by MD Biosciences on Feb 19, 2019 10:26:36 AM

 A novel, rapid in-vitro assay for the screening of compound effects                                                              in nerve injury

Neurite outgrowth is the projection and extension of axonal processes from neuronal cell bodies. Through this process, neurons organize themselves into highly-complex functional networks connected synaptically to one another.


Modulation of this neurite outgrowth process (neuritogenesis) has been implicated in a wide range of CNS diseases, including neurodegenerative disorders such as spinal cord injuries, Parkinson’s Disease and Stroke.

 

MD Biosciences has developed a cell-based platform using primary cells extracted from adult rat, to evaluate the effect of tested compounds in the presence of inhibitory factors. The assay’s unique characteristics enable yielding more translatable results, which can serve as a predictive tool of the compounds’ efficacy in older animals and eventually in humans.

MD Biosciences offers an in-vitro assay to evaluate the effect of potential therapeutics on neurite outgrowth and connectivity (synaptic formation) in primary neuronal cell culture. 

image001


                                                                                     Neurite outgrowth after spinal cord injury in adult animal (Day 7)
Unique Screen Characteristics:

  1. Assays on spinal cord and cortex cell culture
  2. Primary neuronal cells extracted from adult animals
  3. Fast turnaround with results available in approximately 7 days
  4. Primary readout:  number of developed cells and the length of neurites in the presence of the tested compound and vehicle

Call or contact us today for our special introductory price of $1900 per compound. 

Contact Us!

 

Read More

Topics: Neuro/CNS, assays, Neuroscience, Nerve Injury

Preclinical Efficacy Models of Parkinson's Disease: 6OHDA & Acute MPTP

Posted by MD Biosciences on Aug 11, 2011 10:03:00 PM

MD Biosciences, a Preclinical Contract Research Organization (CRO), offers in vivo models for the study of Parkinson's Disease (PD). The 6-OHDA and acute MPTP models for PD have been well characterized with the underlying mechanisms of toxicity well understood. Both models are useful tools in evaluating potential neuroprotective therapies providing the ability to target any differences in motor activities and determine whether a drug differentially affects a specific motor behavior.

Parkinson's Disease Background 
Parkinson's Disease (PD) is typically an adult-onset progressive neurodegenerative movement disorder that affects millions of people worldwide. Pathologically, PD is characterized by the profound and specific loss of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNpc) of the midbrain. Other areas interconnected with the SNpc, the caudate and putamen, collectively known as the striatum, also show remarkable loss of their projection fibers. In accordance with insult to brain regions involved in controlling coordinated movements, the cardinal symptoms of PD include bradykinesia, resting tremor, rigidity, and postural instability. Due to its complex pathology, however, no disease model has yet to faithfully replicate all aspects of human PD. Converging lines of evidence from toxin-induced and genetic models have continued to further our understanding of the pathological processes underlying PD and lend themselves as useful systems for the examination of therapeutic interventions.

PD Whitepaper & Preclinical Efficacy Studies 
MD Biosciences has released a new whitepaperdiscussing the various efficacy models of PD, the underlying mechanisms of each model and their usefulness as tools for the development of new therapies and interventions. Additionally, MD Biosciences offers these classical models of PD as contracted research studies as part of our portfolio of Neurology Discovery Services. A copy of the whitepaper "What in vivo models have revealed about the pathogenesis and treatment of PD" can be downloaded at http://www.mdbiosciences.com

About MD Biosciences 
MD Biosciences is a Preclinical Contract Research Organization (CRO) providing services and products for biotech/pharmaceutical, medical device and animal health and companies engaged in inflammations & neurology research. With specialized laboratories located in Minnesota, Glasgow, and Israel, our panel of internationally recognized experts provides in-depth expertise and technologies to overcome challenges and provide total solutions to the drug discovery market.

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

Topics: Neuro/CNS, efficacy, Parkinsons, Models

MD Biosciences to Showcase Preclinical Capabilities at Neuroscience Conf

Posted by Amy Clausen on Nov 11, 2008 11:15:00 AM


St Paul, MN, November 11, 2008 – MD Biosciences, a global biotechnology company focused in inflammations & neurology research will showcase its pre-clinical capabilities at the 2008 Neuroscience Conference in Washington, DC, November 15 – 19th, 2008, booth 1825. Capabilities included in the showcase are efficacy disease models within Multiple Sclerosis (MS), Gliosis, Parkinson’s Disease, Nociceptive, Neuropathic, Post-operative and Inflammatory Pain.

Multiple Sclerosis:

Multiple sclerosis is a demyelinating disease of the CNS. Due to the clinical and pathological similarities of EAE and MS, EAE has been used as a model for the study of human demyelinating disease and is characterized by a relapsing-remitting disease course with subsequent progressive disability.

  • MBP-induced EAE
  • MOG-induced EAE
  • PLP-induced EAE.

Gliosis:

Gliosis is a proliferation of astrocytes in the central nervous system (CNS) in response to injury which results in scar formation. Astrocytes react to injury by hypertrophy and up-regulation of the glial-fibrillary acidic protein. Gliosis, along with neuronal loss, is a prominent feature of many diseases of the central nervous system.

Parkinson’s Disease:

Parkinon's Disease (PD) is a neurogenerative disorder characterized by reduction in striatial (DA) content caused by the loss of dopaminergenic neurons in the Substantia Nigra part compacta (SNpc) and their proportions to the striatum.

  • Acute MPTP
  • Chronic MPTP
  • 6-OHDA

Pain:
MD Biosciences offers Nociceptive, Neuropathic and Inflammatory Pain models:.

  • Tail Flick
  • Visceral Pain
  • Caspaicin
  • Post-operative pain
  • Chronic Constriction Injury (CCI, Bennett & Xie)
  • Taxol induced Neuropathic Pain
  • Spinal Nerve Ligation (Chung)
  • STZ Diabetic Neuropathy
  • Carrageenan Induced Inflammatory Pain
  • Adjuvant (CFA) induced Inflammatory Pain
  • Arthritic and Monoarthritic Pain.

 

About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland and has specialized laboratories located in the United States, United Kingdom, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

 ### 

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.


Read More

Topics: Neuro/CNS